About Alzheimer’s Disease

Alzheimer’s disease is an irreversible, neurodegenerative disorder leading to disabling impairment of memory and cognitive skills. Alzheimer’s disease is the most common cause of dementia among older adults. Masitinib is currently investigated in mild to moderate forms of Alzheimer’s disease.

Currently, there is no satisfactory treatment for mild and moderate forms of Alzheimer’s disease. Therefore, this remains an area of significant unmet medical need.

Masitinib positioning in Alzheimer’s Disease

Masitinib is positioned in the treatment of mild and moderate Alzheimer’s disease, that is to say, for patients already having clinical signs of dementia. Masitinib is not positioned in prodromal (pre-symptomatic) forms of the disease.

The rationale for evaluating masitinib in Alzheimer’s disease is based on masitinib’s inhibition of the c-Kit, Lyn, Fyn and CSF1R kinases.

Number of patients targeted by masitinib in Alzheimer’s Disease

The number of patients targeted by masitinib amounts to 5,000,000 in Europe and in the US.

Positive Phase 2 results of masitinib in Alzheimer’s Disease

AB Science reported positive Phase 2A proof of concept results with masitinib in Alzheimer’s disease. In this study, masitinib showed a decrease of the decline of cognitive function and an improvement in daily living activities. The results of the study have been published in the Alzheimer’s Research & Therapy.

Current Phase 2B/3 study with masitinib in Alzheimer’s Disease

A phase 2B/3 study is on-going to assess the safety and efficacy of masitinib in patients with confirmed mild to moderate Alzheimer’s disease. In this study, masitinib is given as add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine. The enrolment for this study has been completed and all patients have completed the last study visit.